Clinical human trials begin for COVID-19 vaccine in China

[xuxu1457]

GLOBALink | China hits 400 mln vaccine doses following recent COVID-19 outbreak

More than 100 million doses of the vaccine in the past nine days, 11 million doses a day.

 

[JSCh]

How many different vaccines are being administered to population in China? Do you guys get to choose which vaccine you want to take?

The major one are Cansino, sinopharm and sinovac vaccine.
And choices would depend on location and vaccine availability. Some could have choices sometime right away, sometimes if they are willing to wait, but not always.

 

[JSCh]

https://twitter.com/x/status/1397066010318884865

People's Daily, China @PDChina
China state-affiliated media

China's Kangtai Bio on Monday signed a deal with Chilean institutions to carry out the Phase III clinical trials in Chile for inactivated #COVID19 vaccine. Kangtai Bio vaccine has been approved for emergency use in China.


1:44 PM · May 25, 2021

 

[JSCh]

https://twitter.com/x/status/1397679946303082496

Hilda Bastian, PhD @hildabast

The #4Humanity phase 3 trial of Sinopharm's Beijing & Wuhan vaccines published in JAMA by @NawalAlKaabi &co https://jamanetwork.com/journals/jama/fullarticle/2780562… HT @swiftshoes

WIV04 = Wuhan: efficacy 14 days+ after dose 2, 72.8% (58-82) HB02 = Beijing: 78.1% (65-86) Control group was vax adjuvant ...1/n



...Wuhan vax 12,743; Beijing 12,726; control 12,737. Just under 16% were women, <2% were aged 60 & over

Primary efficacy outcome (in tweet 1) was symptomatic Covid-19: 26 in Wuhan group, 21 in Beijing, 95 in control.

Severe Covid-19: 0 in vaxed groups, 2 in control group ...2/n

6:24 AM · May 27, 2021

https://twitter.com/x/status/1397741848953692166

 

[JSCh]

https://twitter.com/x/status/1397772703289856001

China Xinhua News @XHNews
China state-affiliated media

HeadlinesWatch: Khaleej Times http://bit.ly/3vunEZ1 - Pakistan has started production of China's single-dose #Covid19 vaccine CanSino at the National Institute of Health (NIH) plant that was set up in April


12:32 PM · May 27, 2021

 

[JSCh]

China approves fourth COVID-19 vaccine for emergency use
By Global Times
Published: Mar 15, 2021 11:15 PM

Photo: Institute of Microbiology, Chinese Academy of Sciences

China has approved the fourth COVID-19 vaccine for emergency use, a Chinese hamster ovary (CHO) cell vaccine jointly developed by experts from the Chinese Centers for Disease Control and Prevention (China’s CDC) and the Chinese Academy of Sciences (CAS), the academy announced Monday.

On February 22, the Uzbek legislature approved the Emergency Use Authorization (EUA) for the vaccine in Uzbekistan. The vaccine was approved for use on March 1. Uzbekistan rates the vaccine as one of the safest and most effective in the world.

The vaccine, developed by a team led by Gao Fu, director of China’s CDC, is one of the five technical routes, laid out by the scientific research team of the State Council, for the joint prevention and control mechanism of COVID-19.

The academy’s statement said the vaccine completed phases I and II of the clinical trials in October 2020. The results showed that there were no serious adverse reactions after complete inoculation. The neutralizing antibody level produced by the vaccine was comparable to that of other recombinant protein vaccines and mRNA vaccines currently used worldwide, meeting advanced international standards.

Phase III of clinical trials of the vaccine was launched in China, Uzbekistan, Pakistan, Ecuador and Indonesia, in November 2020, with 29,000 participants scheduled to be vaccinated.

The Phase III of the clinical trial is progressing well, particularly with high recognition from Uzbekistan, the country where the trial was first started, the statement said.

The CHO cell vaccine does not require a high-level biosafety laboratory production facility. The production process is stable and reliable, and production can be quickly increased at home and abroad, significantly reducing production costs, and is convenient for storage and transportation.

Three-shot recombinant COVID-19 vaccines available in Beijing
Source: Xinhua| 2021-05-28 14:11:15|Editor: huaxia

BEIJING, May 28 (Xinhua) -- A China-developed recombinant protein COVID-19 vaccine that requires to be administered in three shots has been made available in Beijing.

The vaccine (CHO Cells) was jointly developed by the Institute of Microbiology under the Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. Starting Thursday, the researchers from the institute have received the first jab in Beijing's Haidian District.

China issued emergency use authorization of the vaccine on March 10, and people from many provinces including Anhui and Hubei have been vaccinated since then. On May 3, the first batch of the vaccine was rolled off the production line in Beijing, according to the institute.

The results of phase-2 trials, which involved people aged between 18 and 59, show that 83 percent of the participants produced neutralizing antibodies after two doses of the vaccine, and 97 percent produced neutralizing antibodies after three doses.

The early-stage trials conducted among people aged 60 and above show that the seroconversion rate of neutralizing antibodies reached 95 percent after three doses, with no serious adverse reactions related to vaccination.

The level of neutralizing antibody elicited by the vaccine is comparable to other COVID-19 recombinant protein vaccines and mRNA vaccines globally, the institute said in a statement.

Recombinant protein vaccine does not need a high-grade biosafety laboratory for manufacture, and can quickly achieve large-scale production. It is more cost-efficient and easier to store and transport, the vaccine maker said.

 

[JSCh]

BRICS vaccine center opens in Beijing
Source: Xinhua| 2021-05-29 00:09:30|Editor: huaxia

BEIJING, May 28 (Xinhua) -- The BRICS Vaccine R&D Center-China Center was launched by Sinovac Research and Development Co., Ltd. Friday in Beijing.

The center will combine online and offline methods to promote joint research, vaccine development and testing, and factory building. It will also promote authorized production and mutual recognition of standards between Brazil, Russia, India, China, and South Africa, the Beijing-based company said.

Sinovac supplied 540 million doses of the COVID-19 vaccine CoronaVac to China and nearly 40 countries and regions worldwide, accounting for about a quarter of the total global supply. Nearly 400 million doses of CoronaVac have been administered globally, data showed.

 

[JSCh]

https://twitter.com/x/status/1399588949031489543

Global Times @globaltimesnews
China state-affiliated media

Chinese vaccine producer #Sinopharm rolled out the first batch of its #COVID19 #vaccines for COVAX on Tuesday. Sinopharm’s vaccine was approved by @WHO for emergency use on May 7.

 

[JSCh]

https://twitter.com/x/status/1399397206981894145

Immunization of Serrana´s population with Butantan´s vaccine has a high decrease of 80% cases and 95% in deaths by COVID-19

Immunization of Serrana´s population with Butantan´s vaccine has a high decrease of 80% cases and 95% in deaths by COVID-19

butantan.gov.br

 

[JSCh]

https://twitter.com/x/status/1399737026291789824

CGTN @CGTNOfficial
China state-affiliated media

#BREAKING WHO has approved China's #Sinovac #COVID19 vaccine for emergency use.


10:38 PM · Jun 1, 2021

 

[JSCh]

https://twitter.com/x/status/1399916177263140864

China News 中国新闻网 @Echinanews
China state-affiliated media

#Pakistan launched the locally produced Chinese CanSino COVID-19 #vaccine on Tuesday. Chinese Ambassador to Pakistan @AmbNong said the vaccine cooperation between China and Pakistan adds to the efforts of building a global community of health for all. https://bit.ly/3iaIfxO




10:30 AM · Jun 2, 2021

 

[JSCh]

https://twitter.com/x/status/1399738467911831553

 

[JSCh]

Sinopharm can provide more than 1 bln COVID-19 shots beyond China in second half of year

China National Pharmaceutical Group (Sinopharm) has the capacity to provide more than 1 billion COVID-19 vaccine doses to the world beyond China in the second half of this year, the firm's chairman Liu Jingzhen said late on Wednesday.

www.reuters.com

 

[JSCh]

https://twitter.com/x/status/1400507573019635713

Global Times @globaltimesnews
China state-affiliated media

A #COVID19 nasal spray #vaccine has applied for emergency use in China, prominent vaccine developer Chen Wei revealed on Thu. It is only 1/5 the amount of the injectable vaccine and doesn’t need cold-chain transport, Chen said.

Update: Vaccine targeting strain first detected in S. Africa applies for clinical application in China: Chen Wei - Global Times

www.globaltimes.cn

1:40 AM · Jun 4, 2021

 

[JSCh]

https://twitter.com/x/status/1400822100722552841

Global Times @globaltimesnews
China state-affiliated media

#China has approved emergency use of #Sinovac's #CoronaVac vaccine on children aged 3-17. Sinovac has finished phase I and II clinical research on this age group, which proved the #vaccine is as safe and efficient as it is for adults, Sinovac Chairman Yin Weidong said on Fri.


10:29 PM · Jun 4, 2021